Gottardis MM - Search Results

1

Drug safety is a barrier to the discovery and development of new androgen receptor antagonists.

Foster WR, Car BD, Shi H, Levesque PC, Obermeier MT, Gan J, Arezzo JC, Powlin SS, Dinchuk JE, Balog A, Salvati ME, Attar RM, Gottardis MM. Foster WR, et al. Among authors: gottardis mm. Prostate. 2011 Apr;71(5):480-8. doi: 10.1002/pros.21263. Epub 2010 Sep 28. Prostate. 2011. PMID: 20878947

2

Identification of a novel class of androgen receptor antagonists based on the bicyclic-1H-isoindole-1,3(2H)-dione nucleus.

Salvati ME, Balog A, Wei DD, Pickering D, Attar RM, Geng J, Rizzo CA, Hunt JT, Gottardis MM, Weinmann R, Martinez R. Salvati ME, et al. Among authors: gottardis mm. Bioorg Med Chem Lett. 2005 Jan 17;15(2):389-93. doi: 10.1016/j.bmcl.2004.10.051. Bioorg Med Chem Lett. 2005. PMID: 15603960

3

Identification of novel functional inhibitors of 17beta-hydroxysteroid dehydrogenase type III (17beta-HSD3).

Spires TE, Fink BE, Kick EK, You D, Rizzo CA, Takenaka I, Lawrence RM, Ruan Z, Salvati ME, Vite GD, Weinmann R, Attar RM, Gottardis MM, Lorenzi MV. Spires TE, et al. Among authors: gottardis mm. Prostate. 2005 Oct 1;65(2):159-70. doi: 10.1002/pros.20279. Prostate. 2005. PMID: 15924334

4

Identification and optimization of a novel series of [2.2.1]-oxabicyclo imide-based androgen receptor antagonists.

Salvati ME, Balog A, Shan W, Rampulla R, Giese S, Mitt T, Furch JA, Vite GD, Attar RM, Jure-Kunkel M, Geng J, Rizzo CA, Gottardis MM, Krystek SR, Gougoutas J, Galella MA, Obermeier M, Fura A, Chandrasena G. Salvati ME, et al. Among authors: gottardis mm. Bioorg Med Chem Lett. 2008 Mar 15;18(6):1910-5. doi: 10.1016/j.bmcl.2008.02.006. Epub 2008 Feb 8. Bioorg Med Chem Lett. 2008. PMID: 18291644

5

Discovery of BMS-641988, a novel and potent inhibitor of androgen receptor signaling for the treatment of prostate cancer.

Attar RM, Jure-Kunkel M, Balog A, Cvijic ME, Dell-John J, Rizzo CA, Schweizer L, Spires TE, Platero JS, Obermeier M, Shan W, Salvati ME, Foster WR, Dinchuk J, Chen SJ, Vite G, Kramer R, Gottardis MM. Attar RM, et al. Among authors: gottardis mm. Cancer Res. 2009 Aug 15;69(16):6522-30. doi: 10.1158/0008-5472.CAN-09-1111. Epub 2009 Aug 4. Cancer Res. 2009. PMID: 19654297

6

Design and synthesis of 4-[3,5-dioxo-11-oxa-4,9-diazatricyclo[5.3.1.0(2,6)]undec-4-yl]-2-trifluoromethyl-benzonitriles as androgen receptor antagonists.

Xiao HY, Balog A, Attar RM, Fairfax D, Fleming LB, Holst CL, Martin GS, Rossiter LM, Chen J, Cvjic ME, Dell-John J, Geng J, Gottardis MM, Han WC, Nation A, Obermeier M, Rizzo CA, Schweizer L, Spires T Jr, Shan W, Gavai A, Salvati ME, Vite G. Xiao HY, et al. Among authors: gottardis mm. Bioorg Med Chem Lett. 2010 Aug 1;20(15):4491-5. doi: 10.1016/j.bmcl.2010.06.034. Epub 2010 Jun 10. Bioorg Med Chem Lett. 2010. PMID: 20584610

7

Structure based approach to the design of bicyclic-1H-isoindole-1,3(2H)-dione based androgen receptor antagonists.

Salvati ME, Balog A, Shan W, Wei DD, Pickering D, Attar RM, Geng J, Rizzo CA, Gottardis MM, Weinmann R, Krystek SR, Sack J, An Y, Kish K. Salvati ME, et al. Among authors: gottardis mm. Bioorg Med Chem Lett. 2005 Jan 17;15(2):271-6. doi: 10.1016/j.bmcl.2004.10.085. Bioorg Med Chem Lett. 2005. PMID: 15603938

8

The androgen receptor can signal through Wnt/beta-Catenin in prostate cancer cells as an adaptation mechanism to castration levels of androgens.

Schweizer L, Rizzo CA, Spires TE, Platero JS, Wu Q, Lin TA, Gottardis MM, Attar RM. Schweizer L, et al. Among authors: gottardis mm. BMC Cell Biol. 2008 Jan 24;9:4. doi: 10.1186/1471-2121-9-4. BMC Cell Biol. 2008. PMID: 18218096 Free PMC article.

9

The synthesis and evaluation of [2.2.1]-bicycloazahydantoins as androgen receptor antagonists.

Balog A, Salvati ME, Shan W, Mathur A, Leith LW, Wei DD, Attar RM, Geng J, Rizzo CA, Wang C, Krystek SR, Tokarski JS, Hunt JT, Gottardis M, Weinmann R. Balog A, et al. Bioorg Med Chem Lett. 2004 Dec 20;14(24):6107-11. doi: 10.1016/j.bmcl.2004.09.049. Bioorg Med Chem Lett. 2004. PMID: 15546739

10

Insulin receptor (IR) pathway hyperactivity in IGF-IR null cells and suppression of downstream growth signaling using the dual IGF-IR/IR inhibitor, BMS-754807.

Dinchuk JE, Cao C, Huang F, Reeves KA, Wang J, Myers F, Cantor GH, Zhou X, Attar RM, Gottardis M, Carboni JM. Dinchuk JE, et al. Endocrinology. 2010 Sep;151(9):4123-32. doi: 10.1210/en.2010-0032. Epub 2010 Jul 7. Endocrinology. 2010. PMID: 20610571

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

120 results

Search Page

Filters